SCHEMBL2139141

SCHEMBL2139141

C1C2CC1O2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23916928 0.76
SCHEMBL18695288 0.76 CYP2C9 (0.32)
SCHEMBL2142701 0.76
SCHEMBL23030281 0.76
SCHEMBL16878021 0.76
SCHEMBL9675320 0.76
SCHEMBL16877718 0.73
SCHEMBL17798886 0.73
SCHEMBL21278859 0.73
SCHEMBL3596893 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1794129-B1 Synthesis by chiral diamine-mediated asymmetric alkylation JANSSEN PHARMACEUTICA NV (BE) 2015-12-30 EP claimed
EP-1794129-A4 SYNTHESIS BY CHIRAL DIAMINE-MEDIATED ASYMMETRIC ALKYLATION JANSSEN PHARMACEUTICA NV (BE) 2009-09-02 EP claimed
US-7402670-B2 Synthesis by chiral diamine-mediated asymmetric alkylation JANSSEN PHARMACEUTICA, N.V. (BE) 2008-07-22 US claimed
EP-1794129-A2 SYNTHESIS BY CHIRAL DIAMINE-MEDIATED ASYMMETRIC ALKYLATION JANSSEN PHARMACEUTICA N.V. (BE) 2007-06-13 EP claimed
WO-2006039383-A2 SYNTHESIS BY CHIRAL DIAMINE-MEDIATED ASYMMETRIC ALKYLATION JANSSEN PHARMACEUTICA N.V. (BE) 2006-04-13 WO claimed
US-20060069250-A1 Synthesis by chiral diamine-mediated asymmetric alkylation DENG XIAOHU 2006-03-30 US claimed
WO-2026107349-A1 HETEROCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASES ANTARES THERAPEUTICS, INC. (US) 2026-05-21 WO disclosed
US-20260132129-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR TREATING CANCER GENESIS THERAPEUTICS INC (US) 2026-05-14 US disclosed
US-20260130925-A1 METHODS FOR TREATING CANCER GENESIS MOLECULAR AI INC (US) 2026-05-14 US disclosed
CN-122029160-A Method for preparing PI3K inhibitor 蝎子疗法股份有限公司 2026-05-12 CN disclosed
US-20260125366-A1 METHODS FOR TREATING CANCER SCORPION THERAPEUTICS INC (US) 2026-05-07 US disclosed
EP-4727938-A1 BICYCLIC HETEROAROMATIC COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS Prothena Biosciences Limited (IE) 2026-04-22 EP disclosed
EP-4727939-A1 5-(CINNOLIN-6-YL)THIAZOLE COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS Prothena Biosciences Limited (IE) 2026-04-22 EP disclosed
EP-1637530-A1 THERAPEUTIC AGENT FOR SENILE DEMENTIA Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-03-22 EP disclosed
US-20040039208-A1 Process for making n-aryl-anthranilic acids and their derivatives CHEN MICHAEL HUAI GU (US) 2004-02-26 US disclosed
EP-1313694-A1 PROCESS FOR MAKING N-ARYL-ANTHRANILIC ACIDS AND THEIR DERIVATIVES WARNER-LAMBERT COMPANY (US) 2003-05-28 EP disclosed
WO-2002018319-A1 PROCESS FOR MAKING N-ARYL-ANTHRANILIC ACIDS AND THEIR DERIVATIVES WARNER-LAMBERT COMPANY LLC (US) 2002-03-07 WO disclosed
EP-0464846-B1 Imide derivatives, and their production and use SUMITOMO PHARMA (JP) 1998-04-22 EP disclosed
US-5532372-A Imide derivatives, and their production and use SUMITOMO PHARMACEUTICALS COMPANY, LTD. (JP) 1996-07-02 US disclosed
EP-0464846-A1 Imide derivatives, and their production and use SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1992-01-08 EP disclosed